Last reviewed · How we verify
rAd-p53
At a glance
| Generic name | rAd-p53 |
|---|---|
| Also known as | p53 gene therapy |
| Sponsor | Shenzhen SiBiono GeneTech Co.,Ltd |
| Modality | Small molecule |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- Formatting the Risk Prediction Models for Never-Smoking Lung Cancer
- Evaluation of the Diagnostic and Prognostic Role of PET (PET/CT and PET/MRI) in Gynecological Tumors.
- SCH-58500 in Treating Patients With Primary Ovarian, Fallopian Tube, or Peritoneal Cancer (C95084) (PHASE1)
- p53 Gene Therapy in Treatment of Diabetes Concurrent With Hepatocellular Carcinoma (PHASE2)
- Trans-catheter Arterial Embolization Combined With p53 Gene Therapy for Treatment of Advanced Hepatocellular Carcinoma (PHASE2)
- P53 Gene Combined With Radio- and Chemo-therapy in Treatment of Unresectable Locally Advanced Head and Neck Cancer (PHASE2)
- Trans-catheter Chemo-embolization Combined With rAd-p53 Gene Injection in Treatment of Advanced Hepatocellular Carcinoma (PHASE2)
- Paclitaxel Plus Carboplatin With or Without SCH-58500 in Treating Patients With Newly Diagnosed Stage III Ovarian or Stage III Primary Peritoneal Cancer (PHASE2, PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- rAd-p53 CI brief — competitive landscape report
- rAd-p53 updates RSS · CI watch RSS
- Shenzhen SiBiono GeneTech Co.,Ltd portfolio CI